勵晶太平洋(00575.HK)商業戰略伙伴獲國家藥監局批准提交試驗性新藥申請 批准早泄藥SENSTEND在中國市場推廣的重要里程碑
2020年12月2日,作為專業保健、健康和生命科學的投資集團,勵晶太平洋集團有限公司(“勵晶太平洋”或“本公司”及其附屬公司,統稱“本集團”;股份代號﹕0575.HK)欣然宣佈其於中國之商業戰略伙伴及一間上海復星醫藥之完全控制公司江蘇萬邦醫藥營銷有限責任公司(“江蘇萬邦醫藥”)已獲得國家藥品監督管理局(“國家藥品監督管理局”)批准提交試驗性新藥申請以就一款許可產品開展人類臨牀試驗。
根據與江蘇萬邦醫藥的許可協議條款,勵晶太平洋現有權從江蘇萬邦醫藥收取80萬美元(約624萬港元)的款項。此款項應在30個營業日內支付。國家藥品監督管理局將正式審閲臨牀試驗審批,而審評中心之臨牀試驗審批將會於2021年第一季度完結之前取得。另一筆320萬美元(約合2496萬港元)的款項將於成功獲得國家藥品監督管理局批准開始臨牀試驗後收取。
勵晶太平洋行政總裁Jamie Gibson表示:“此認可絕對是批准在中國市場推廣Senstend™之重要里程碑。我們將繼續與其現有及潛在商業夥伴全力緊密配合,並在有任何新進展時適時通知股東及潛在投資者。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.